🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to researchers.

An International Health Concern

Cases of gonorrhoea are on the rise globally, with figures suggesting more than 82 million instances per year. Notably increased rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Gain Authorization

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization marks a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Data and Worldwide Availability

As per data detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which uses a dual-drug approach. The research included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the rights to register and commercialise the drug in many developing nations.

Clinicians directly involved have voiced optimism. The availability of a single-dose, oral treatment such as this is seen as a "game-changer" for gonorrhoea control. This is deemed crucial to reduce the burden of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.